Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Other EventsItem 8.01 Other Events.
On June25, 2018, Stemline Therapeutics,Inc. announced it completed the submission of its BiologicsLicense Application (BLA) for ELZONRIS (tagraxofusp; SL-401), a targeted therapy directed to the interleukin-3 receptor (CD123), to the U.S. Food and Drug Administration (FDA).
A copy of the press release is being furnished as Exhibit99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
The following exhibit is furnished herewith:
STEMLINE THERAPEUTICS INC ExhibitEX-99.1 2 a18-16033_1ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS (tagraxofusp; SL-401) for the Treatment of BPDCN NEW YORK,…To view the full exhibit click here
About Stemline Therapeutics,Inc. (NASDAQ:STML)
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.